Argos Therapeutics Inc (NASDAQ:ARGS) has earned an average recommendation of “Hold” from the six brokerages that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation and one has assigned a buy recommendation to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $4.47.

A number of analysts have weighed in on ARGS shares. Zacks Investment Research raised shares of Argos Therapeutics from a “hold” rating to a “buy” rating and set a $0.50 price target for the company in a report on Tuesday, May 2nd. Stifel Nicolaus downgraded shares of Argos Therapeutics from a “buy” rating to a “hold” rating and set a $1.40 price target for the company. in a report on Wednesday, February 22nd. FBR & Co reissued a “hold” rating on shares of Argos Therapeutics in a report on Thursday, February 23rd. Needham & Company LLC downgraded shares of Argos Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, February 22nd. Finally, JMP Securities downgraded shares of Argos Therapeutics from an “outperform” rating to a “market perform” rating in a report on Wednesday, February 22nd.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another site, it was copied illegally and reposted in violation of United States and international trademark and copyright laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/06/06/argos-therapeutics-inc-args-given-average-recommendation-of-hold-by-brokerages.html.

Shares of Argos Therapeutics (NASDAQ ARGS) traded down 1.80% during midday trading on Tuesday, hitting $0.41. 332,776 shares of the company were exchanged. The stock’s market cap is $16.95 million. Argos Therapeutics has a one year low of $0.31 and a one year high of $8.29. The stock’s 50-day moving average is $0.44 and its 200-day moving average is $2.59.

An institutional investor recently raised its position in Argos Therapeutics stock. Vanguard Group Inc. raised its position in Argos Therapeutics Inc (NASDAQ:ARGS) by 8.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 847,123 shares of the biopharmaceutical company’s stock after buying an additional 64,787 shares during the period. Vanguard Group Inc.’s holdings in Argos Therapeutics were worth $382,000 at the end of the most recent quarter. Institutional investors and hedge funds own 15.25% of the company’s stock.

Argos Therapeutics Company Profile

Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.

Receive News & Ratings for Argos Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.